SAIT101

BIOLOGICAL2 trials

Sponsors

Archigen Biotech Limited

Conditions

Lymphoma, FollicularRheumatoid Arthritis

Phase 1

PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis

CompletedNCT02819726

Archigen Biotech LimitedRheumatoid Arthritis

Start: 2016-10-11End: 2018-11-07Updated: 2020-02-17

Phase 3

A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma

CompletedNCT02809053

Archigen Biotech LimitedLymphoma, Follicular

Start: 2017-01-18End: 2020-01-10Updated: 2020-10-08

Related Papers

Efficacy and safety of rituximab biosimilar (DRL_RI) versus MabThera <sup>®</sup> in low-tumor-burden follicular lymphoma: the FLINTER study

Therapeutic Advances in Medical Oncology2025-01-01